Introduction
The intrinsic breast cancer subtypes, including Luminal A, Luminal B, HER2-enriched, and Basal-like cancers, show distinct risk factor profiles and are hypothesized to be independent diseases within the breast [1, 2] . Ductal histologic subtype, diagnosed in up to 80% of invasive breast tumors [3] [4] [5] , is approximately 50% Luminal A intrinsic subtype. While Basal-like and HER2-enriched intrinsic subtype tumors represent a minority of breast tumors, up to 20 andsubtype and are rarely lobular or mixed ductal/lobular histologic subtypes [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Lobular and mixed ductal-lobular breast cancers, diagnosed in up to 15% of cases each [3] [4] [5] , tend to be 80-90% Luminal A intrinsic subtype [3] [4] [5] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Thus, there are strong associations between histologic and intrinsic subtype.
Previous studies of etiologic heterogeneity according to histology have suggested that lobular disease is more strongly associated with a number of reproductive risk factors and hormone-modulating exposures including younger age at menarche [18] [19] [20] [21] [22] , older age at menopause [19, 22, 23] , premenopausal status [23] [24] [25] , combined estrogen and progesterone (E + P) hormone therapy (HT) use [26] [27] [28] [29] , and later age at first birth [18-22, 26, 28, 30] . The strongest differences in association for reproductive risk factors and lobular disease have been observed for combined hormone therapy use (odds ratios for current E + P HT use versus never range from 2.1 to 2.3 for lobular and 1.1-1.8 for ductal [27, 29] ) and older age at first birth (case-control odds ratios for > 30 versus ≤ 19 years of age range from 1.8 to 2.4 for lobular disease and 1.1-1.6 for ductal disease) [18-22, 26, 28, 30] . However, it is unclear if the observed associations depend on intrinsic breast cancer subtypes, which also have unique reproductive risk factor profiles [6, 7] . We sought to disentangle the associations between reproductive breast cancer risk factors and breast cancer subtype, considering both histology and Luminal A subtype in the Carolina Breast Cancer Study phases 1-3 (1993-2013) .
Methods

Study population
The present analysis includes 3,655 cases of invasive breast cancer from the Carolina Breast Cancer Study (CBCS) Phases 1-3 (1993-2013) . The CBCS is a population-based study among black and non-black women, initiated in 1993, that recruited participants from 24 (CBCS 1-2) to 44 (CBCS 3) of the 100 North Carolina counties [31] . CBCS oversampled women less than 50 years of age and black women [9, 32] .
For CBCS1-3, case eligibility criteria included women with a first diagnosis of breast cancer [invasive or in situ (CBCS2 only)], aged 20-74 years at diagnosis, and residence in specified counties. Cases were enrolled following rapid case ascertainment from the NC Central Cancer Registry, and controls (CBCS1-2) were identified using DMV and Medicare lists. Controls were frequency matched to cases by race and 5-year age group. All participants provided informed consent for study enrollment, and cases granted access to tumor tissue blocks/slides and medical records from treatment centers. Self-report, risk factor data were collected during in-person interviews by a trained study nurse. Cases eligible for this analysis had invasive tumor tissue available for centralized pathology review and were classified as ductal (n = 2,856), lobular (n = 326), or mixed ductal/lobular (n = 473) (henceforth referred to as mixed) breast cancer. The study maintains Institutional Review Board approval at the University of North Carolina.
Histologic subtype
Histologic subtype for CBCS1-3 was determined via centralized pathologist review. Tumors classified as ductal, lobular, and mixed ductal-lobular comprise 84% of all CBCS1-3 cases with histologic subtype available. Ductal or lobular histologic subtype tumors were defined as at least 80% representative of that histology. Mixed tumors contained ≥ 20% of one histologic subtype and < 80% of the second histologic subtype. The following histologic subtypes were excluded: mixed ductal/non-lobular (n = 285), mucinous (n = 89), mixed ductal/metaplastic (n = 63), metaplastic (n = 44), DCIS w/focal invasion (n = 44), undifferentiated high grade (n = 29), tubular (n = 23), micropapillary (n = 21), papillary (n = 19), medullary (n = 18), pleomorphic lobular (n = 17), anaplastic (n = 14), apocrine (n = 11), cribriform (n = 9), neuroendocrine (n = 3), and others (n = 15). Cases with unknown (n = 99) or missing (n = 376) were also excluded.
Immunohistochemistry (IHC)-based clinical breast cancer subtypes
For CBCS1-2, estrogen receptor (ER) and progesterone receptor (PR) status was abstracted from medical records for 80% of cases. The remaining 20% of cases with tumor tissue available had ER and PR status determined using IHC, which was performed at UNC. For tissue that was stained at UNC, a study pathologist determined ER and PR positivity using contemporaneous clinical cut-points [9] . HER2 staining was performed at UNC for all CBCS1-2 cases with available tissue as described previously. HER2 positivity was defined as in ≥ 10% of tumor cells displaying weak or greater intensity of membrane/membrane plus cytoplasmic staining [9] .
In CBCS3, 98% of cases had ER, PR, and HER2 information in their medical records. For the remaining 2% of cases without medical record ER, PR, and HER2 data, IHC data were used. IHC staining was performed at UNC with positivity cut-points of ≥ 10% for ER and PR status. HER2 positivity was defined as 3 + staining intensity [negativity was defined as 0/1+ (equivocal cases with 2 + staining were excluded)], as described in Allott et al. [33] .
For CBCS1-3, three-marker clinical subtypes were defined as follows: Luminal A (ER+ or PR+ and HER2−), Luminal B (ER+ or PR+ and HER2+), Triple Negative (TN) (ER− and PR− and HER2−), and HER2+ (ER− and PR− and HER2+).
Statistical analyses
Patient characteristics
The associations between histologic subtype and race, age, menopausal status, and clinical subtype were estimated using generalized linear models that were adjusted for age, race, and study phase (1, 2, 3) [34] . Relative frequency differences (RFDs), interpretable as the percentage difference between index and referent groups, and 95% confidence intervals (95% CIs) were estimated as the measure of association [34] . To account for the CBCS sampling design, weighted percentages are presented alongside unweighted sample size counts. Patient characteristics were defined as follows: race [self-report: black, non-black (> 98% white, henceforth referred to as white)], age (years) (< 40, 40-49, 50-59, ≥ 60), menopausal status (pre-, post-), and clinical subtype as defined above.
Reproductive risk factor analyses
The association between each reproductive breast cancer risk factor and histologic subtype was estimated in case-control (CBCS1-2) and case-case (CBCS1-3) analyses. Polytomous logistic regression was used to obtain odds ratios (ORs) and 95% confidence intervals (95% CIs) as the measure of association. The following risk factors were studied in association with histologic breast cancer subtype: parity (nulliparous, 1, 2, ≥ 3), years since last birth (defined as age at diagnosis/enrollment minus age at last birth; among parous women only) (0-≤ 10, 10-≤ 20, > 20), age at first live birth (years) (parous women only) (< 26, ≥ 26), lifetime lactation duration (months) (parous women only) (never, 0-≤ 12, > 12), oral contraceptive use (never, former, current), and hormone therapy (HT) use [never, estrogen alone, combined estrogen + progesterone (E + P)]. Additional variables used in case-control analyses included study phase (1, 2, 3), age continuous , family history of breast cancer (yes, no), alcohol intake (ever, never), smoking duration (years) (never, < 10, 11-19, ≥ 20), oral contraceptive use (ever, never), breastfeeding (ever, never), age at menarche (years) (< 13, ≥ 13), and the offset term to account for the sampling design of CBCS. Case-case analyses are presented for CBCS1-3 to assess etiologic heterogeneity by histologic subtype [6, 35] . In case-case analyses, ductal served as the referent group for lobular and mixed. Case-case models are adjusted for age, race, and study phase.
We tested the null hypothesis that the slope of the line equals zero for age at diagnosis, parity, and lactation duration, each modeled as continuous variables. We conducted a race-stratified sensitivity analysis of the risk factor-histologic subtype associations, but we were unable to assess racial differences in oral contraceptive and HT use due to low sample size among black women for current OC use and combined E + P use. All analyses were done in SAS version 9.4 (SAS Institute, Cary, NC). p values were produced for a two-sided test with an alpha of 0.05 for statistical significance.
Results
Women from the CBCS Phases 1-3 displayed patterns consistent with established histological associations by age, race, menopausal status, and clinical subtype (Table 1) . Relative to ductal histologic subtype, lobular and mixed tumors We observed unique risk factor patterns for lobular tumors relative to ductal tumors ( Table 2 ). Ductal tumors were inversely associated with parity, increasing lactation duration, and estrogen-only hormone therapy (HT) use. Among lobular tumors, parity was inversely associated with having one child versus being nulliparous, but the association was attenuated as parity increased. We observed a positive association between age ≥ 26 years at first birth and lobular disease [Lobular OR: 1. To assess whether these risk factor patterns were indicative of significant etiologic differences between ductal (referent) and lobular disease, we conducted case-case analyses. Case-case analyses showed a statistically significant difference in the associations between lobular and ductal disease for age ≥ 26 years at first birth 
Discussion
In the Carolina Breast Cancer Study, we observed differences in reproductive risk factor profiles between ductal and lobular invasive breast cancers. Lobular disease was consistently, positively associated with > 10 and up to 20 years since last birth, older age (≥ 26 years) at first birth, lactation duration greater than 12 months, oral contraceptive use, and combined estrogen plus progesterone (E + P) hormone therapy (HT) use. These associations did not vary by race and were not altered by restriction to Luminal A tumors only, suggesting that histology and molecular subtype contribute to observed risk factor associations for breast cancer.
In agreement with the previous literature, we found that relative to ductal cancers, lobular cancers were less frequent among black versus white women [36] [37] [38] [39] , less frequent among younger women [22, [36] [37] [38] [40] [41] [42] [43] , but more common among premenopausal women after controlling for age [23] [24] [25] . As has been shown previously, we observed that 88% of lobular tumors in our study were Luminal A subtype, which closely matches previous studies of lobular tumors (~80-90%, [7, 8, 11, 15, 17, 44, 45] ), and is considerably higher than the overall prevalence of Luminal A subtype among invasive breast cancers (50%, [6, 7] ). We also found that ductal tumors displayed diversity in clinical subtype and contained a majority of the TN and HER2+ tumor types, as others have reported [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] .
Associations between histology and a number of reproductive risk factors among women from the CBCS were similar to associations reported elsewhere. We and others have shown lobular tumors are more strongly associated with older age at first birth with ORs ranging from 1.8 to 2.4 for lobular disease and 1.1-1.6 for ductal disease in other studies [18, 19, 21, 22, 26, 28, 30] . We also observed an increased risk of lobular disease for women who reported using oral contraceptives. These findings are similar to a larger study by Newcomer et al. who included nearly 500 cases of lobular disease, and observed that for former versus never OC use, only lobular histology showed a positive association with Table 2 Case-control and case-case odds ratios (OR) and 95% confidence intervals (95% CI) for the association between parity, years since last birth, lactation duration, oral contraceptive use, and hormone therapy use comparing lobular and ductal histologic subtype breast tumors to controls (CBCS1-2) and lobular to ductal histologic subtype breast tumors (CBCS1-3) Risk factor OC use [21, 46, 47] . Additionally, we observed an increased risk of lobular disease among current users of combined E + P HT compared to ductal disease, with similar magnitude and direction to previous reports [26] [27] [28] [29] .
In case-case analyses, lobular tumors were significantly associated with older age at first birth, lactation duration greater than 12 months, and current OC use suggesting that these risk factors may contribute to etiologic differences between ductal and lobular tumors. Even after restricting to the predominant lobular clinical subtype, Luminal A, the aforementioned risk factor associations persisted, which mirrors the work by Kotsopoulos et al. who reported risk factor associations among lobular tumors persisted after restricting to ER+ and PR+ tumors [28] . Concerning lactation duration and risk of lobular disease, our findings differed from those reported previously in case-control studies where slightly inverse (OR 0.9) or null associations for lactation duration and lobular disease have been reported [18, 19, 47, 48] . We found that among parous women only, lactation duration greater than 12 months was significantly associated with lobular disease relative to ductal, even after restricting to Luminal A subtype in our case-case analyses. Previous studies have included more women over the age of 50 and had lower proportions of women who reported never breastfeeding (30-40%) than was observed in our study (50%) [18, 19, 47, 48] . Generational differences in breastfeeding practices and geographic variation of breastfeeding initiation [49] may contribute to the observed differences in the literature for lactation duration and lobular carcinoma. Overall, our study supports different risk factor profiles between ductal and lobular tumors, particularly for risk factors that are thought to impact hormone levels.
The findings for invasive lobular carcinoma displaying consistent associations with a host of hormone-modulating, reproductive risk factors and independent of Luminal A subtype beg the question: is histologic subtype etiologic in origin or is it a result of selective pressures in the breast that encourage a tumor to develop into one histologic subtype over another? Intrinsic breast cancer subtypes are hypothesized to be etiologic in nature with Luminal A and B arising from the luminal epithelial cells of the mammary gland and Basal-like and HER2-enriched arising from the basal cells of the mammary gland [2] . Conversely, histologic subtype is subjective in nature and determined by a pathologist from the visual appearance of the epithelial cells where ductal histology is characterized by tubules and solid nests of epithelial cells and lobular carcinoma is characterized by a non-cohesive phenotype with single-file strands of epithelial cells scattered throughout the stroma [5, 42] . Lobular carcinomas are characterized by downregulation of E-cadherin in > 90% of cases; however, this can also be observed in a smaller percentage of ductal carcinomas [40] . Therefore, it is not clear that histologic subtype is truly etiologic in Bold values estimate exclude the null value a Adjusted for race (black, white), age (continuous), study phase (1, 2, 3), family history (yes, no), alcohol intake (ever, never), smoking duration (never, < 10 years, 11-19, ≥ 20) , Oral contraceptive use (ever, never), breastfeeding (ever, never), menopausal status (pre-, post-), age at menarche (< 13, ≥ 13), CBCS offset term nature or if histology is a result of exposure to phenotypemodulating selective pressures present in breast tissue over the life course. Our study should be interpreted in light of some limitations. We were unable to include rare histologic subtypes (e.g., medullary, papillary, metaplastic) in our analyses due to limited sample sizes. Because lobular tumors are predominantly Luminal A subtype, we were unable to study differences in risk factor profiles between lobular tumors that were of Triple Negative or HER2+ subtype. We, like other studies of histology, acknowledge some uncertainty around histologic classification. Interobserver reliability for histologic subtype is reported to be around 80% [50] , possibly leading to some instability in associations across studies. We sought to eliminate this problem by using centralized pathology review to classify CBCS invasive breast tumors into histologic subtypes, by focusing on tumors that had a dominant ductal or lobular phenotype (at least 80% ductal or lobular), and by considering mixed ductal-lobular tumors separately. This may have impacted our power, though, and TCGA found that molecularly, mixed tumors were not a distinct disease and displayed genomic features classifying them as ductal-or lobular-like [8] . Therefore, applying these molecular classifications to mixed ductal-lobular tumors in epidemiologic studies may be a step toward better characterizing risk factor profiles for mixed tumors.
To conclude, we observed differences in risk factor profiles between ductal and lobular tumors in the CBCS that persisted after restricting to Luminal A subtype. Using both case-control and case-case analyses, we found that lobular tumors have unique risk factor profiles from ductal tumors when considering older age at first birth, increasing lactation duration, current oral contraceptive use, and combined E + P HT use. When we restricted to Luminal A subtype, we found that the observed reproductive risk factor-histologic subtype associations were not altered. Overall, our findings suggest potential etiologic or phenotype-modulating differences between ductal and lobular disease that are not driven by intrinsic subtype alone. Our findings strengthen the evidence that lobular tumors are sensitive to hormonemodulating exposures.
